» Articles » PMID: 35650297

Identification of Hub Pathways and Drug Candidates in Gastric Cancer Through Systems Biology

Overview
Journal Sci Rep
Specialty Science
Date 2022 Jun 1
PMID 35650297
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer is the fourth cause of cancer death globally, and gastric adenocarcinoma is its most common type. Efforts for the treatment of gastric cancer have increased its median survival rate by only seven months. Due to the relatively low response of gastric cancer to surgery and adjuvant therapy, as well as the complex role of risk factors in its incidences, such as protein-pomp inhibitors (PPIs) and viral and bacterial infections, we aimed to study the pathological pathways involved in gastric cancer development and investigate possible medications by systems biology and bioinformatics tools. In this study, the protein-protein interaction network was analyzed based on microarray data, and possible effective compounds were discovered. Non-coding RNA versus coding RNA interaction network and gene-disease network were also reconstructed to better understand the underlying mechanisms. It was found that compounds such as amiloride, imatinib, omeprazole, troglitazone, pantoprazole, and fostamatinib might be effective in gastric cancer treatment. In a gene-disease network, it was indicated that diseases such as liver carcinoma, breast carcinoma, liver fibrosis, prostate cancer, ovarian carcinoma, and lung cancer were correlated with gastric adenocarcinoma through specific genes, including hgf, mt2a, mmp2, fbn1, col1a1, and col1a2. It was shown that signaling pathways such as cell cycle, cell division, and extracellular matrix organization were overexpressed, while digestion and ion transport pathways were underexpressed. Based on a multilevel systems biology analysis, hub genes in gastric adenocarcinoma showed participation in the pathways such as focal adhesion, platelet activation, gastric acid secretion, HPV infection, and cell cycle. PPIs are hypothesized to have a therapeutic effect on patients with gastric cancer. Fostamatinib seems a potential therapeutic drug in gastric cancer due to its inhibitory effect on two survival genes. However, these findings should be confirmed through experimental investigations.

Citing Articles

Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.

Wang M, Li J, Yang X, Yan Q, Wang H, Xu X Cancer Gene Ther. 2023; 30(11):1485-1497.

PMID: 37542132 DOI: 10.1038/s41417-023-00653-8.


A systems biology approach to pathogenesis of gastric cancer: gene network modeling and pathway analysis.

Mottaghi-Dastjerdi N, Ghorbani A, Montazeri H, Guzzi P BMC Gastroenterol. 2023; 23(1):248.

PMID: 37482618 PMC: 10364406. DOI: 10.1186/s12876-023-02891-4.


A systems biology approach for discovering the cellular and molecular aspects of psychogenic non-epileptic seizure.

Malekpour M, Jafari A, Kashkooli M, Salarikia S, Negahdaripour M Front Psychiatry. 2023; 14:1116892.

PMID: 37252132 PMC: 10213457. DOI: 10.3389/fpsyt.2023.1116892.


Transforming RNA-Seq gene expression to track cancer progression in the multi-stage early to advanced-stage cancer development.

Livesey M, Rossouw S, Blignaut R, Christoffels A, Bendou H PLoS One. 2023; 18(4):e0284458.

PMID: 37093793 PMC: 10124877. DOI: 10.1371/journal.pone.0284458.


Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study.

Xiang Q, Xie Q, Liu Z, Mu G, Zhang H, Zhou S Clin Transl Med. 2022; 12(12):e1104.

PMID: 36453946 PMC: 9714378. DOI: 10.1002/ctm2.1104.

References
1.
Negahdaripour M, Eslami M, Nezafat N, Hajighahramani N, Ghoshoon M, Shoolian E . A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches. Infect Genet Evol. 2017; 54:402-416. DOI: 10.1016/j.meegid.2017.08.002. View

2.
Bussel J, Arnold D, Grossbard E, Mayer J, Trelinski J, Homenda W . Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93(7):921-930. PMC: 6055608. DOI: 10.1002/ajh.25125. View

3.
Wang X, Zhou Q, Yu Z, Wu X, Chen X, Li J . Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin β1-FAK signaling pathway. Int J Cancer. 2017; 141(5):998-1010. DOI: 10.1002/ijc.30801. View

4.
Rao S, Solum G, Niederdorfer B, Norsett K, Bjorkoy G, Thommesen L . Gastrin activates autophagy and increases migration and survival of gastric adenocarcinoma cells. BMC Cancer. 2017; 17(1):68. PMC: 5251222. DOI: 10.1186/s12885-017-3055-5. View

5.
Thrumurthy S, Chaudry M, Hochhauser D, Mughal M . The diagnosis and management of gastric cancer. BMJ. 2013; 347:f6367. DOI: 10.1136/bmj.f6367. View